Genprex, Inc. (GNPX) Form 10-Q — May 13, 2026
Genprex reported a net loss of $4.46 million for the three months ended March 31, 2026, compared to a loss of $3.96 million in the prior year period, driven by increased clinical trial activities and operating expenses. The company recorded zero revenue, remaining a clinical-stage entity with product candidates REQORSA for oncology and GPX-002 for diabetes. The company strengthened its balance sheet during the quarter, raising approximately $13.4 million in net proceeds through its At-The-Market (ATM) equity facility. Cash and cash equivalents increased to $18.0 million as of March 31, 2026, up from $7.8 million at year-end 2025.
Key figures
- Revenue
- 0
- Total Assets
- 20306266
- Cash Position
- 18049255
- Shares Outstanding
- 9044856
- Cash Runway
- Second half of 2027
- Atm Net Proceeds
- 13356857
Price after filing
Close on the filing date to close N calendar days later (from $0.85). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.